1h agoInvesting.com Analyst RatingsBULLISH 63Analyst
Cantor Fitzgerald reiterates Overweight on BioMarin stock at $86
Cantor Fitzgerald reiterates Overweight on BioMarin stock at $86
Why Is BIOMARIN PHARMACEUTI (BMRN) Stock Moving Today?
By the Top Tier Newswire AI Desk · reviewed against 22 wire stories
BIOMARIN PHARMACEUTI (BMRN) is drawing unusual attention today. Our newswire has captured 22 stories on BMRN across 10 sources in the last 36 hours, with AI sentiment reading mixed (avg 48/100).
Public view, delayed 4h. Every headline, price and sentiment read below — and this write-up itself — reaches Pro subscribers live. Public readers see it once it clears the delay.
The written analysis for BMRN publishes to the public page once it clears the 4-hour delay. The coverage, sentiment and session data below are already here.
BMRN by the numbers
7 sessions: +5.98%Coverage: 22 stories / 10 sourcesAI sentiment: 48/100 (mixed)
The headlines behind the move
2h agoThe FlyBEARISH 34Analyst
Biomarin Price Target Lowered To 60 From 62 At Rbc Capital
2h agoThe FlyBEARISH 34Analyst
BioMarin price target lowered to $89 from $94 at Wedbush
2h agoThe FlyBEARISH 38Analyst
BioMarin price target lowered to $94 from $97 at Oppenheimer
2h agoThe FlyBEARISH 34Analyst
BioMarin price target lowered to $83 from $86 at BofA
3h agoThe FlyBEARISH 34Analyst
BioMarin price target lowered to $66 from $70 at Stifel
3h agoThe FlyBEARISH 38Analyst
BioMarin price target lowered to $119 from $122 at Morgan Stanley
3h agoInvestorsHubBEARISH 42Earnings
BioMarin Beats Q3 Revenue Forecasts but Cuts 2026 Outlook on Voxzogo Timing and Deal Costs
BioMarin (NASDAQ:BMRN) beats Q3 revenue estimates with $1.025 billion in sales but cuts 2026 revenue and EPS guidance amid Voxzogo order timing and deal costs.
4h agoInvesting.com Analyst RatingsBEARISH 34Analyst
Oppenheimer lowers BioMarin stock price target to $94 on guidance cut
Oppenheimer lowers BioMarin stock price target to $94 on guidance cut
4h agoInvesting.com Analyst RatingsBEARISH 34Analyst
Stifel cuts BioMarin stock price target to $66 on growth concerns
Stifel cuts BioMarin stock price target to $66 on growth concerns
Frequently asked questions
Why is BMRN stock moving today?
BIOMARIN PHARMACEUTI (BMRN) is drawing unusual attention today. Our newswire has captured 22 stories on BMRN across 10 sources in the last 36 hours, with AI sentiment reading mixed (avg 48/100). The most recent driver: "Cantor Fitzgerald reiterates Overweight on BioMarin stock at $86" (Investing.com Analyst Ratings).
Is BMRN a buy right now?
Top Tier Newswire does not give financial advice. Our AI sentiment across the last 36 hours of BMRN coverage reads 48/100 over 22 stories; treat it as a research signal and do your own diligence.
How fast does this page update?
The data sections refresh continuously as the newswire lands coverage; the written analysis is published once per trading day. Pro subscribers additionally get real-time push alerts, watchlists, and the full live terminal.
More moves explained today
- Why is IBTA up today (+31.06%)
- Why is AEHR up today (+25.75%)
- Why is STVN down today (-25.73%)
- Why is IT down today (-18.10%)
- Why is BETA up today (+16.22%)
- Why is GPK up today (+15.70%)
Want the next move before the crowd? The live terminal streams every headline in real time with watchlist alerts, AI sentiment, and the full data stack behind this page.Get Pro Access →
More on BMRN: full news and sentiment history. Sentiment scores are AI-derived research signals, not financial advice.